ZEB1 and cancer: It is generally known that expression of ZEB1 (the well-characterized key activator of EMT) by cancer cells endows them a more aggressive phenotype, including enhanced invasive capacities, therapeutic resistance, and stemness properties, resulting in poor clinical outcomes in a variety of human cancer types261–263 (Fig. 2).